Is petrelintide the future of obesity treatment?
Obesity is as a serious medical condition linked to a range of related comorbidities such as cardiovascular disease, type 2 diabetes and certain cancers. The Danish biotech company Zealand Pharma, believe that their new obesity drug petrelintide, which is currently in clinical development holds potential as a treatment option for weight management. They also believe it will address unmet needs for people living with obesity or being overweight, offer new hope and provide an overall better patient experience.
Zealand Pharma have collaborated with Roche Pharmaceuticals to co-develop and bring to market petrelintide, as announced in a recent press release. This latest news will help place Zealand Pharma as a key player in the future management of obesity. Lets take a deeper look into this drug and its future in obesity treatment.
š The story so far GLP-1 receptor agonists
The weight loss market has been dominated by pharmaceutical companies such as Novo Nordisk and Eli Lilly with their GLP-1 (glp-1 receptor agonists) anti-obesity drugs, Wegovy (semaglutide) and Zepbound (tirzepatide).
The primary mechanism of action of Wegovy and Mounjaro is through the activation of GLP-1 receptors. By stimulating these receptors, these medications can increase insulin secretion, decrease appetite and slow down gastric emptying. This combination of effects helps to reduce calorie intake and promote weight loss.
These drugs were hailed as game-changers in obesity treatment, but now petrelintide is on the horizon, promising to shake up the weight loss medication market. What is petrelintide and how does it work? Read on to find out more.
š What is petrelintide?
Petrelintide belongs to a class of drugs that bind to and activate the amylin receptor and are called long-acting amylin analog. This once-weekly subcutaneous administration drug is a peptide designed to be a long-acting version of amylin, a hormone in the body that plays a role in regulating blood glucose levels and appetite. Clinical and preclinical data for petrelintide shows, by activating the amylin receptor, sensitivity to the satiety hormone leptin can be restored, a hormone that signals satiety. Rather than suppressing appetite, Zealand says its drug helps patients feel full faster.
As a result, Roche and Zealand believe petrelintide could deliver body weight reduction comparable to glucagon-like peptide 1 (GLP-1) receptor agonists, but with improved tolerability and without the side effects associated with GLP-1 drugs.
š What are the results of the petrelintide clinical trial?
Phase 1 trial
In a 16-week, Phase 1, multiple ascending dose (MAD) clinical trial, Zealand reported that petrelintide led to an average 8.3% loss in body weight for the highest of three doses tested, versus a 1.7% average weight loss for the placebo group. All gastrointestinal adverse events were mild, except for two moderate nausea and vomiting events reported in one participant, who discontinued treatment.
The MAD trial showed no serious or severe adverse events (AEs) and no withdrawals from treatment. The most frequent related adverse events were decreased appetite, early satiety, food aversion and nausea. These all were mild, transient and most had an onset within 2 days of the first dose. These MAD trial results were presented at the Obesity Society Annual Meeting (ObesityWeek) in 2024.
Phase 2 trials
ZUPREME-1 is a clinical trial investigating petrelintide in obese/overweight people without type 2 diabetes and was launched in December 2024.
ZUPREME-2 is a clinical trial which will investigate the drug in obese/overweight people with type 2 diabetes, planned for later in the first half of this year.
š” The future for petrelintide
Amylin analog petrelintide is emerging as an important therapeutic option for chronic weight management. The drug is unlikely to be released or face regulatory approval for several years as petrelintide is still in its early clinical development.
š Conclusion
Obesity is one of the greatest healthcare challenges faced by society, but there is new hope with petrelintide ahead. Zealand Pharmaās partnership with Roche is a bold step forward in the obesity treatment space, signalling the potential for ground breaking advancements in both weight loss and associated health conditions.
Sources
- Zealand Pharma and Roche enter collaboration and license
- Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
- Zealand Pharma announces first participant enrolled inĀ
Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Can I Trust NowPatient
Our product and services are certified to international healthcare, medical device and data security standards
Medicines Experts
Meet our medical team
We are a broad skilled and passionate group of clinicians with experience of operating in health systems in the United Kingdom & United States. Providing excellent care and advice is at the heart of everything we do. You can read more about our medical team by visiting the medical teamĀ page or learn more about how we curate content by visiting ourĀ editorial process
WHY WE BUILT NOWPATIENT
We are committed to helping everyone, everywhere live healthier lives
The NowPatient virtual care platform provides you with access to trusted health information, affordable treatments, management of chronic health conditions and continuous monitoring for health risks. NowPatient can be accessed by downloading the App or using your web browser.
Download our app today
Your Questions Answered
For your peace of mind, we can answer your questions quickly
What does NowPatient do?
NowPatientĀ is an online pharmacy & telehealth service that is available in the US and UK. Our service is FREE and packed with useful features that can help you save money on the cost of your medications, access virtual treatments, and provide tools that can help improve your overall health.
Get started today and benefit fromĀ medication reminders,Ā Get Treated Privately,Ā NHS online pharmacy,Ā GP appointment booking,Ā Rx savings card,Ā Drug Coupons,Ā US drug savings programs,Ā health conditions information,Ā genetic testing,Ā home test kits,Ā BMI Risks,Ā Type 2 Diabetes Risks,Ā pollen meter,Ā air quality monitor, and lots more!
Our service is operated by experienced medical professionals in the United States and the United Kingdom. You can view the online services that we provide by clickingĀ Features.
UK users can safely and securely buy medicines online that treat a wide range of medical conditions. UK customers can also order NHS prescriptions online with the benefit of free tracked delivery.
US customers, regardless of insurance coverage, can enjoy huge savings on prescription medications using our various drug savings programs including drug coupons, savings card and manufacturer-sponsored patient assistance programs.
Where is NowPatient located?
NowPatient has offices in the United Kingdom and United States.
In the UK, we are located at:
NowPatient
28 Chipstead Valley Road
Coulsdon
Surrey
CR52RA
In the US, we are located at:
NowPatient
8911 North Capital of Texas Highway
Suite 4200 #1263
78759
Austin, TX
How can I contact NowPatient?
To contact NowPatient, please use the contact form available on theĀ Contact UsĀ page.
Alternatively, if you need to speak to us, you can reach us on the following numbers:
UK telephone number āĀ 020 388 51 500
US telephone number āĀ 1-866-967-1977
Who owns NowPatient?
NowPatient is owned and operated byĀ Infohealth Ltd, a licensed online pharmacy with services spanning the UK, US and Rest of the World. Infohealth Ltd is registered in England and Wales under company number 04004930 and our registered office is at Lynwood House, 373 ā 375 Station Road, Harrow, England, HA1 2AW.
Our website isĀ www.nowpatient.com. Our App is called āNowPatientā and can be downloaded from the App Store (for Apple devices) or Google Play (for Android devices).
Can you tell me more about your NHS online pharmacy?
NowPatientās Pharmaceutical services in the UK are provided by Infohealth Limited trading as āInfohealth Pharmacyā.
Our dispensing pharmacy is regulated and authorized for internet sales by the General Pharmaceutical Council (GPhC), registration numberĀ 1036487. You can view our license credentials on theĀ General Pharmaceutical Council website. Our superintendent pharmacist who is responsible for the safe and effective oversight of medicines supplies is Mr Amish Patel (Registration Number 2042705).
Medicines are not ordinary items of commerce. All medicines or healthcare product sales are made under the supervision of a registered pharmacist who is licensed by the GPhC. At all times, we endeavour to provide a professional and transparent service whose primary goal is to ensure that the best interests of the patient are served.
How do I make a complaint?
From time to time, we accept that our service levels may not be up to your expectations. NowPatient welcomes concerns, compliments and complaints as valuable feedback that will help us learn from your experiences and make improvements. Feedback can be provided via our clear and transparent Complaints Procedures.
Can you tell me more about NowPatientās prescribing services for treatments offered?
Our prescribing services are regulated by the General Pharmaceutical Council (GPhC). We provide the following regulated activity:
ā¢ treatment of disease, disorder, or injury
ā¢ transport services, triage, and medical advice are provided remotely
ā¢ caring for adults over 65 years old
ā¢ caring for adults under 65 years old
NowPatient prescribing services are run by Infohealth Limited. The Clinical Safety Officer and nominated individual is Mr Navin Khosla.
Can you tell me more about NowPatientās US services?
Our head of US services isĀ Dr. Jamie Winn.
You can lower the cost of your prescription medications using our various savings programs which include drug coupons, savings card and manufacturer-sponsored patient assistance programs.
We do not provide any prescribing services or dispensing services in the United States.
Is NowPatient legit and can I trust information from NowPatient?
Yes. NowPatient provides trustworthy and accessible clinical, health education and prescription services. We are also trusted by the NHS to deliver clinical and NHS repeat prescription dispensing across the whole of England. In the United States, we work with over 65,000 pharmacies to deliver considerable costs savings for our users.
NowPatient is operated by experienced licensed medical professionals in the United Kingdom and United States. Our Medical TeamĀ can be found here.
Our service is trusted by thousands of patients worldwide. You can read their reviews on our Trustpilot:
What are NowPatientās opening hours?
OurĀ office hoursĀ are:
UK ā Monday-Friday 9am-6pm GMT
US ā Monday-Friday 8am-5pm EST
Please note that we are closed at weekends.
In the event of a medical life-threatening emergency please call:
UK ā 999
US ā 911
In the event of a medical emergency which is not life-threatening please call:
UK ā 111